Skip to main content

Table 1 Clinical and demographic characteristics of the study population at baseline

From: Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

 

Placebo (N = 332)

Rup 10 mg (N = 662)

Rup 20 mg (N = 476)

Age (years), mean (SD)

33.0 (11.9)

32.5 (10.9)

33.2 (11.3)

Sex (women), n (%)

158 (47.6)

352 (53.2)

260 (54.6)

Weight (kg), mean (SD)

71.5 (15.4)

70.0 (14.9)

70.5 (14.9)

Height (cm), mean (SD)

169.8 (11.1)

168.9 (9.8)

168.5 (10.0)

Days of treatment, mean (SD)

17.9 (8.0)

16.7 (6.2)

14.3 (3.2)

T4NSS (0–12), mean (SD)

8.1 (1.8)

7.9 (1.8)

7.9 (1.9)

T2OSS (0–6), mean (SD)

3.2 (1.5)

2.9 (1.7)

2.8 (1.8)

T6SS (0–18), mean (SD)

11.3 (2.8)

10.8 (2.9)

10.6 (3.1)

  1. Rup Rupatadine, T4NSS Total 4 Nasal Symptom Score, T2OSS Total 2 Ocular Symptom Score, T6SS Total 6 Symptom Score, SD standard deviation